Login to Your Account

Exelixis, Genentech Enter $16M Deal Around Notch

By Randall Osborne

Monday, June 6, 2005
A month after pulling down $35 million from a briskly advancing cancer deal with GlaxoSmithKline plc, Exelixis Inc. has signed a collaboration with Genentech Inc. to target proteins and genes involved in cell proliferation and differentiation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription